Summary:
The purpose of this study is to learn about the effects of a new study drug XEn1101 for treating depression symptoms and to find the best dose for treating MDD and to see how safe the drug is for participants with MDD and to see if XEN1101 helps to improve anhedonia and anxiety symptoms.
Qualified Participants Must:
• Be between the ages of 18 and 65
•
Be experiencing symptoms of depression
Qualified Participants May Receive:
If you qualify, you may receive investigational medication and study-related procedures from a local doctor. Reimbursement for time and travel related to study participation may be provided.